

This spreadsheet is updated monthly and enables self-audit
of a medicines formulary for adherence to current NICE Technology Appraisals.
All guidelines refer to adults unless indicated.

Technology appraisals 30
ICB commissioned 5
Non-ICB commissioned 16
Not applicable 5
ICB commissioned and approved 1 (20%)
Average days to compliance 15

Title	Recommendation	Published	Type	Implement	Commissioner	ICB decision	Compliance	Notes	Local information
Subcutaneous spesolimab 1-ml formulation for preventing generalised pustular psoriasis flares in people 12 years and over (terminated appraisal) [TA1144]	Terminated appraisal	08/04/2026	TA					N/A	Terminated appraisal
Pembrolizumab for neoadjuvant and adjuvant treatment of resectable locally advanced head and neck squamous cell carcinoma [TA1145]	Recommended	21/04/2026	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts	NHS England
Ripretinib for treating advanced gastrointestinal stromal tumours after 3 or more kinase inhibitors [TA1146]	Recommended	21/04/2026	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts	NHS England
Sodium zirconium cyclosilicate for treating hyperkalaemia [TA1148]	Recommended	29/04/2026	TA	28/07/2026	ICB			This technology is commissioned by integrated care boards. Providers are primary care and NHS hospital trusts.	In progress - Amber initiated
Voridenib for treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in people 12 years and over [TA1147]	Recommended	29/04/2026	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts	NHS England
Belantamab mafodotin with bortezomib and dexamethasone for previously treated multiple myeloma [TA1149]	Recommended	30/04/2026	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts	NHS England
Inebilizumab for treating immunoglobulin G4-related disease (terminated appraisal) [TA1151]	Terminated appraisal	06/05/2026	TA					N/A	Terminated appraisal
Encorafenib with binimetinib for treating BRAF V600E mutation-positive advanced non-small-cell lung cancer [TA1150]	Recommended	06/05/2026	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts	NHS England
Oxybutynin hydrochloride for managing neurogenic detrusor overactivity in people 6 years and over with spinal cord injury or spina bifida (terminated appraisal) [TA1154]	Terminated appraisal	07/05/2026	TA					N/A	Terminated appraisal
Zanidatamab for treating HER2-positive advanced biliary tract cancer after 1 or more lines of systemic treatment [TA1153]	Recommended	07/05/2026	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts	NHS England
Semaglutide for reducing the risk of major adverse cardiovascular events in people with cardiovascular disease and overweight or obesity [TA1152]	Recommended	07/05/2026	TA	05/08/2026	ICB			This technology is commissioned by integrated care boards. Providers are primary care and NHS hospital trusts.	In progress
Rozanolizumab for treating antibody-positive generalised myasthenia gravis [TA1155]	Recommended	20/05/2026	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts	NHS England
Osimertinib for treating EGFR mutation-positive unresectable locally advanced non-small-cell lung cancer after platinum-based chemoradiotherapy [TA1156]	Recommended	21/05/2026	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts	NHS England
Givinostat for treating Duchenne muscular dystrophy in people 6 years and over [TA1157]	Recommended	28/05/2026	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts	NHS England
Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer [TA1158]	Recommended	28/05/2026	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts	NHS England

Title	Recommendation	Published	Type	Implement	Commissioner	ICB decision	Compliance	Notes	Local information
Sotatercept for treating pulmonary arterial hypertension [TA1161]	Recommended	03/06/2026	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts	NHS England
Durvalumab with chemotherapy for neoadjuvant and adjuvant treatment then alone for adjuvant treatment of resectable gastric or gastro-oesophageal junction adenocarcinoma [TA1160]	Recommended	03/06/2026	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts	NHS England
Lisocabtagene maraleucel for treating relapsed or refractory large B-cell lymphoma after 2 or more lines of systemic treatment [TA1159]	Recommended	03/06/2026	TA	01/09/2026				This technology is commissioned by NHS England. Providers are NHS hospital trusts	NHS England
Nogapendekin alfa inbakicept with BCG for non-muscle-invasive bladder cancer with carcinoma in situ that is unresponsive to BCG (terminated evaluation) [TA1163]	Terminated appraisal	04/06/2026	TA					N/A	Terminated appraisal
Nusinersen and risdiplam for treating spinal muscular atrophy [TA1162]	Recommended	04/06/2026	TA	02/09/2026				This technology is commissioned by NHS England. Providers are NHS hospital trusts	NHS England
Tisotumab vedotin for treating recurrent or metastatic cervical cancer that has progressed on or after systemic treatment [TA1164]	Recommended	11/06/2026	TA	09/09/2026				This technology is commissioned by NHS England. Providers are NHS hospital trusts	NHS England
Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer [TA1165]	Recommended	16/06/2026	TA	14/09/2026				This technology is commissioned by NHS England. Providers are NHS hospital trusts	NHS England
Mepolizumab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease with raised blood eosinophils [TA1166]	Recommended	17/06/2026	TA	15/09/2026	ICB	02/07/2026	15	This technology is commissioned by integrated care boards. Providers are integrated care boards	Red RAG
Imlunestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer after endocrine therapy (terminated evaluation) [TA1168]	Terminated appraisal	18/06/2026	TA					N/A	Terminated appraisal
Serplulimab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer [TA1167]	Recommended	18/06/2026	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts	NHS England
Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia [TA694]	Recommended	24/06/2026	TA (Update)					NICE updated recommendation 1.1, and sections 2.5 and 2.6, to remove reference to a commercial arrangement and to update the list price for bempedoic acid and bempedoic acid–ezetimibe.	TA update.
Seladelpar for previously treated primary biliary cholangitis [TA1171]	Recommended	24/06/2026	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts	NHS England
Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable [TA1170]	Recommended	24/06/2026	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts	NHS England
Mirvetuximab soravtansine for treating folate receptor-alpha-positive platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer [TA1169]	Recommended	24/06/2026	TA		Non-ICB			This technology is commissioned by NHS England. Providers are NHS hospital trusts	NHS England
Atogepant for treating migraine [TA1172]	Recommended	30/06/2026	TA (Cost comparison)	30/07/2026	ICB			This technology is commissioned by integrated care boards. Providers are primary and secondary care.	In progress